1
|
Sukwattananipaat P, Kuroda H, Yamano-Adachi N, Omasa T. Metabolomic characterization of monoclonal antibody-producing Chinese hamster lung (CHL)-YN cells in glucose-controlled serum-free fed-batch operation. Biotechnol Bioeng 2024; 121:2848-2867. [PMID: 39138873 DOI: 10.1002/bit.28777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Revised: 05/31/2024] [Accepted: 06/09/2024] [Indexed: 08/15/2024]
Abstract
The fast-growing Chinese hamster lung (CHL)-YN cell line was recently developed for monoclonal antibody production. In this study, we applied a serum-free fed-batch cultivation process to immunoglobulin (Ig)G1-producing CHL-YN cells, which were then used to design a dynamic glucose supply system to stabilize the extracellular glucose concentration based on glucose consumption. Glucose consumption of the cultures rapidly oscillated following three phases of glutamine metabolism: consumption, production, and re-consumption. Use of the dynamic glucose supply prolonged the viability of the CHL-YN-IgG1 cell cultures and increased IgG1 production. Liquid chromatography with tandem mass spectrometry-based target metabolomics analysis of the extracellular metabolites during the first glutamine shift was conducted to search for depleted compounds. The results suggest that the levels of four amino acids, namely arginine, aspartate, methionine, and serine, were sharply decreased in CHL-YN cells during glutamine production. Supporting evidence from metabolic and gene expression analyses also suggest that CHL-YN cells acquired ornithine- and cystathionine-production abilities that differed from those in Chinese hamster ovary-K1 cells, potentially leading to proline and cysteine biosynthesis.
Collapse
Affiliation(s)
| | - Hirotaka Kuroda
- Graduate School of Engineering, Osaka University, Osaka, Japan
- Shimadzu Corp., Kyoto, Japan
- Shimadzu Analytical Innovation Research Laboratories, Osaka, Japan
| | - Noriko Yamano-Adachi
- Graduate School of Engineering, Osaka University, Osaka, Japan
- Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan
- Manufacturing Technology Association of Biologics (MAB), Hyogo, Japan
| | - Takeshi Omasa
- Graduate School of Engineering, Osaka University, Osaka, Japan
- Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan
- Manufacturing Technology Association of Biologics (MAB), Hyogo, Japan
| |
Collapse
|
2
|
Wolnick NQ, Dickson MR, Webster TA, Connolly RP, Fernandes N, Encheva V, Crittenden H, Hodgkins J, Hadley BC, Palermo G, Hendrick SJ, Newell RA, Gray G, Siltanen C, Armstrong J, Downey BJ, Mason C. Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins. Bioprocess Biosyst Eng 2024; 47:1227-1240. [PMID: 38653840 PMCID: PMC11269418 DOI: 10.1007/s00449-024-02997-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 03/10/2024] [Indexed: 04/25/2024]
Abstract
While monospecific antibodies have long been the foundational offering of protein therapeutics, recent advancements in antibody engineering have allowed for the development of far more complex antibody structures. Novel molecular format (NMF) proteins, such as bispecific antibodies (BsAbs), are structures capable of multispecific binding, allowing for expanded therapeutic functionality. As demand for NMF proteins continues to rise, biomanufacturers face the challenge of increasing bioreactor process productivity while simultaneously maintaining consistent product quality. This challenge is exacerbated when producing structurally complex proteins with asymmetric modalities, as seen in NMFs. In this study, the impact of a high inoculation density (HID) fed-batch process on the productivity and product quality attributes of two CHO cell lines expressing unique NMFs, a monospecific antibody with an Fc-fusion protein and a bispecific antibody, compared to low inoculation density (LID) platform fed-batch processes was evaluated. It was observed that an intensified platform fed-batch process increased product concentrations by 33 and 109% for the two uniquely structured complex proteins in a shorter culture duration while maintaining similar product quality attributes to traditional fed-batch processes.
Collapse
Affiliation(s)
| | | | | | | | - Nancy Fernandes
- Research and Development, Lonza Biologics, Portsmouth, NH, USA
| | | | | | | | - Brian C Hadley
- Research and Development, Lonza Biologics, Portsmouth, NH, USA
| | | | | | - Roy A Newell
- Research and Development, Lonza Biologics, Portsmouth, NH, USA
| | - Genevieve Gray
- Research and Development, Lonza Biologics, Portsmouth, NH, USA
| | | | | | | | - Carrie Mason
- Research and Development, Lonza Biologics, Portsmouth, NH, USA
| |
Collapse
|
3
|
Olin M, Wolnick N, Crittenden H, Quach A, Russell B, Hendrick S, Armstrong J, Webster T, Hadley B, Dickson M, Hodgkins J, Busa K, Connolly R, Downey B. An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers. Biotechnol Prog 2024; 40:e3410. [PMID: 38013663 DOI: 10.1002/btpr.3410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 10/04/2023] [Accepted: 11/01/2023] [Indexed: 11/29/2023]
Abstract
An important consideration for biopharmaceutical processes is the cost of goods (CoGs) of biotherapeutics manufacturing. CoGs can be reduced by dramatically increasing the productivity of the bioreactor process. In this study, we demonstrate that an intensified process which couples a perfused N-1 seed reactor and a fully automated high inoculation density (HID) N stage reactor substantially increases the bioreactor productivity as compared to a low inoculation density (LID) control fed-batch process. A panel of six CHOK1SV GS-KO® CHO cell lines expressing three different monoclonal antibodies was evaluated in this intensified process, achieving an average 85% titer increase and 132% space-time yield (STY) increase was demonstrated when comparing the 12-day HID process to a 15-day LID control process. These productivity increases were enabled by automated nutrient feeding in both the N-1 and N stage bioreactors using in-line process analytical technologies (PAT) and feedback control. The N-1 bioreactor utilized in-line capacitance to automatically feed the bioreactor based on a capacitance-specific perfusion rate (CapSPR). The N-stage bioreactor utilized in-line Raman spectroscopy to estimate real-time concentrations of glucose, phenylalanine, and methionine, which are held to target set points using automatic feed additions. These automated feeding methodologies were shown to be generalizable across six cell lines with diverse feed requirements. We show this new process can accommodate clonal diversity and reproducibly achieve substantial titer uplifts compared to traditional cell culture processes, thereby establishing a baseline technology platform upon which further increases bioreactor productivity and CoGs reduction can be achieved.
Collapse
Affiliation(s)
- Mikayla Olin
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| | - Nicolas Wolnick
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| | | | - Anthony Quach
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| | - Brian Russell
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| | | | - Julia Armstrong
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| | - Thaddaeus Webster
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Brian Hadley
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Marissa Dickson
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Jessica Hodgkins
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Kevin Busa
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Roger Connolly
- Research and Development, Lonza Biologics, Portsmouth, New Hampshire, USA
| | - Brandon Downey
- Research and Development, Lonza Biologics, Bend, Oregon, USA
| |
Collapse
|
4
|
Xiang S, Zhang J, Yu L, Tian J, Tang W, Tang H, Xu K, Wang X, Cui Y, Ren K, Cao W, Su Y, Zhou W. Developing an ultra-intensified fed-batch cell culture process with greatly improved performance and productivity. Biotechnol Bioeng 2024; 121:696-709. [PMID: 37994547 DOI: 10.1002/bit.28605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 10/31/2023] [Accepted: 11/06/2023] [Indexed: 11/24/2023]
Abstract
Intensified fed-batch (IFB), a popular cell culture intensification strategy, has been widely used for productivity improvement through high density inoculation followed by fed-batch cultivation. However, such an intensification strategy may counterproductively induce rapidly progressing cell apoptosis and difficult-to-sustain productivity. To improve culture performance, we developed a novel cell culture process intermittent-perfusion fed-batch (IPFB) which incorporates one single or multiple cycles of intermittent perfusion during an IFB process for better sustained cellular and metabolic behaviors and notably improved productivity. Unlike continuous perfusion or other semi-continuous processes such as hybrid perfusion fed-batch with only early-stage perfusion, IPFB applies limited times of intermittent perfusion in the mid-to-late stage of production and still inherits bolus feedings on nonperfusion days as in a fed-batch culture. Compared to IFB, an average titer increase of ~45% was obtained in eight recombinant CHO cell lines studied. Beyond IPFB, ultra-intensified IPFB (UI-IPFB) was designed with a markedly elevated seeding density of 20-80 × 106 cell/mL, achieved through the conventional alternating tangential flow filtration (ATF) perfusion expansion followed with a cell culture concentration step using the same ATF system. With UI-IPFB, up to ~6 folds of traditional fed-batch and ~3 folds of IFB productivity were achieved. Furthermore, the application grounded in these two novel processes showed broad-based feasibility in multiple cell lines and products of interest, and was proven to be effective in cost of goods reduction and readily scalable to a larger scale in existing facilities.
Collapse
Affiliation(s)
| | | | - Le Yu
- Process Development, WuXi Biologics, Wuxi, China
| | - Jun Tian
- Process Development, WuXi Biologics, Wuxi, China
| | - Wenxiu Tang
- Process Development, WuXi Biologics, Wuxi, China
| | - Hao Tang
- Process Development, WuXi Biologics, Wuxi, China
| | - Kecui Xu
- Process Development, WuXi Biologics, Wuxi, China
| | - Xin Wang
- Process Development, WuXi Biologics, Wuxi, China
| | - Yanyan Cui
- Process Development, WuXi Biologics, Wuxi, China
| | - Kaidi Ren
- Process Development, WuXi Biologics, Wuxi, China
| | - Weijia Cao
- Process Development, WuXi Biologics, Wuxi, China
| | - Yuning Su
- Process Development, WuXi Biologics, Wuxi, China
| | - Weichang Zhou
- Waigaoqiao Free Trade Zone, WuXi Biologics, Shanghai, China
| |
Collapse
|
5
|
Martínez VS, Rodriguez K, McCubbin T, Tong J, Mahler S, Shave E, Baker K, Munro TP, Marcellin E. Amino acid degradation pathway inhibitory by-products trigger apoptosis in CHO cells. Biotechnol J 2024; 19:e2300338. [PMID: 38375561 DOI: 10.1002/biot.202300338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 11/25/2023] [Accepted: 12/13/2023] [Indexed: 02/21/2024]
Abstract
Chinese hamster ovary (CHO) cells are widely used to produce complex biopharmaceuticals. Improving their productivity is necessary to fulfill the growing demand for such products. One way to enhance productivity is by cultivating cells at high densities, but inhibitory by-products, such as metabolite derivatives from amino acid degradation, can hinder achieving high cell densities. This research examines the impact of these inhibitory by-products on high-density cultures. We cultured X1 and X2 CHO cell lines in a small-scale semi-perfusion system and introduced a mix of inhibitory by-products on day 10. The X1 and X2 cell lines were chosen for their varied responses to the by-products; X2 was susceptible, while X1 survived. Proteomics revealed that the X2 cell line presented changes in the proteins linked to apoptosis regulation, cell building block synthesis, cell growth, DNA repair, and energy metabolism. We later used the AB cell line, an apoptosis-resistant cell line, to validate the results. AB behaved similar to X1 under stress. We confirmed the activation of apoptosis in X2 using a caspase assay. This research provides insights into the mechanisms of cell death triggered by inhibitory by-products and can guide the optimization of CHO cell culture for biopharmaceutical manufacturing.
Collapse
Affiliation(s)
- Verónica S Martínez
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
| | - Karen Rodriguez
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
| | - Timothy McCubbin
- Queensland Metabolomics and Proteomics (Q-MAP), The University of Queensland, St Lucia, Queensland, Australia
| | - Junjie Tong
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
| | - Stephen Mahler
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
| | - Evan Shave
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
- Patheon, by Thermo Fisher Scientific, Woolloongabba, Queensland, Australia
| | - Kym Baker
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
- Patheon, by Thermo Fisher Scientific, Woolloongabba, Queensland, Australia
| | - Trent P Munro
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
- National Biologics Facility, The University of Queensland, St Lucia, Queensland, Australia
| | - Esteban Marcellin
- ARC Training Centre for Biopharmaceutical Innovation (CBI), Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia
- Queensland Metabolomics and Proteomics (Q-MAP), The University of Queensland, St Lucia, Queensland, Australia
| |
Collapse
|
6
|
Reger LN, Saballus M, Kappes A, Kampmann M, Wijffels RH, Martens DE, Niemann J. A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing. Front Bioeng Biotechnol 2023; 11:1211410. [PMID: 37456731 PMCID: PMC10349264 DOI: 10.3389/fbioe.2023.1211410] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 06/22/2023] [Indexed: 07/18/2023] Open
Abstract
Monoclonal antibodies (mAb) are commonly manufactured by either discontinuous operations like fed-batch (FB) or continuous processes such as steady-state perfusion. Both process types comprise opposing advantages and disadvantages in areas such as plant utilization, feasible cell densities, media consumption and process monitoring effort. In this study, we show feasibility of a promising novel hybrid process strategy that combines beneficial attributes of both process formats. In detail, our strategy comprises a short duration FB, followed by a fast media exchange and cell density readjustment, marking the start of the next FB cycle. Utilizing a small-scale screening tool, we were able to identify beneficial process parameters, including FB interval duration and reinoculation cell density, that allow for multiple cycles of the outlined process in a reproducible manner. In addition, we could demonstrate scalability of the process to a 5L benchtop system, using a fluidized-bed centrifuge as scalable media exchange system. The novel process showed increased productivity (+217%) as well as longer cultivation duration, in comparison to a standard FB with a significantly lower media consumption per produced product (-50%) and a decreased need for process monitoring, in comparison to a perfusion cultivation. Further, the process revealed constant glycosylation pattern in comparison to the perfusion cultivation and has strong potential for further scale-up, due to the use of fully scalable cultivation and media exchange platforms. In summary, we have developed a novel hybrid process strategy that tackles the key challenges of current biomanufacturing of either low productivity or high media consumption, representing a new and innovative approach for future process intensification efforts.
Collapse
Affiliation(s)
- Lucas Nik Reger
- Corporate Research, Sartorius, Göttingen, Germany
- Bioprocess Engineering, Wageningen University, Wageningen, Netherlands
| | | | | | | | - Rene H. Wijffels
- Bioprocess Engineering, Wageningen University, Wageningen, Netherlands
| | - Dirk E. Martens
- Bioprocess Engineering, Wageningen University, Wageningen, Netherlands
| | | |
Collapse
|
7
|
Xu WJ, Lin Y, Mi CL, Pang JY, Wang TY. Progress in fed-batch culture for recombinant protein production in CHO cells. Appl Microbiol Biotechnol 2023; 107:1063-1075. [PMID: 36648523 PMCID: PMC9843118 DOI: 10.1007/s00253-022-12342-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 12/13/2022] [Accepted: 12/15/2022] [Indexed: 01/18/2023]
Abstract
Nearly 80% of the approved human therapeutic antibodies are produced by Chinese Hamster Ovary (CHO) cells. To achieve better cell growth and high-yield recombinant protein, fed-batch culture is typically used for recombinant protein production in CHO cells. According to the demand of nutrients consumption, feed medium containing multiple components in cell culture can affect the characteristics of cell growth and improve the yield and quality of recombinant protein. Fed-batch optimization should have a connection with comprehensive factors such as culture environmental parameters, feed composition, and feeding strategy. At present, process intensification (PI) is explored to maintain production flexible and meet forthcoming demands of biotherapeutics process. Here, CHO cell culture, feed composition in fed-batch culture, fed-batch culture environmental parameters, feeding strategies, metabolic byproducts in fed-batch culture, chemostat cultivation, and the intensified fed-batch are reviewed. KEY POINTS: • Fed-batch culture in CHO cells is reviewed. • Fed-batch has become a common technology for recombinant protein production. • Fed batch culture promotes recombinant protein production in CHO cells.
Collapse
Affiliation(s)
- Wen-Jing Xu
- grid.412990.70000 0004 1808 322XInternational Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang, 453003 Henan China ,grid.412990.70000 0004 1808 322XSchool of Pharmacy, Xinxiang Medical University, Xinxiang, 453003 Henan China
| | - Yan Lin
- grid.412990.70000 0004 1808 322XInternational Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang, 453003 Henan China ,grid.412990.70000 0004 1808 322XSchool of Nursing, Xinxiang Medical University, Xinxiang, 453003 Henan China
| | - Chun-Liu Mi
- grid.412990.70000 0004 1808 322XInternational Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang, 453003 Henan China
| | - Jing-Ying Pang
- grid.412990.70000 0004 1808 322XSchool of the First Clinical College, Xinxiang Medical University, Xinxiang, 453000 Henan China
| | - Tian-Yun Wang
- grid.412990.70000 0004 1808 322XInternational Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang, 453003 Henan China ,grid.495434.b0000 0004 1797 4346School of medicine, Xinxiang University, Xinxiang, 453003 Henan China
| |
Collapse
|
8
|
Schulze M, Kues D, Gao W, Houser M, Scheibenbogen K, Husemann B, Husemann U, Greller G. Automation of Integrated Perfusion Control Simplifying Process Intensification of Mammalian Biomanufacturing in Single‐Use Bioreactors. CHEM-ING-TECH 2022. [DOI: 10.1002/cite.202200101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Markus Schulze
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Dominic Kues
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Wei Gao
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Matthew Houser
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Karl‐Heinz Scheibenbogen
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Bernward Husemann
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Ute Husemann
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| | - Gerhard Greller
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbH August-Spindler-Straße 11 37079 Göttingen Germany
| |
Collapse
|
9
|
Yang Y, Li Z, Li Q, Ma K, Lin Y, Feng H, Wang T. Increase recombinant antibody yields through optimizing vector design and production process in CHO cells. Appl Microbiol Biotechnol 2022; 106:4963-4975. [PMID: 35788878 DOI: 10.1007/s00253-022-12051-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/23/2022] [Accepted: 06/26/2022] [Indexed: 11/28/2022]
Abstract
Chinese hamster ovary (CHO) cells are the most commonly used host cells for the production of recombinant monoclonal antibodies (mAbs) due to their several advantages. Although the yields of recombinant mAbs can be greatly increased by some strategies, such as medium formulation, culture conditions, and cell engineering, most studies focused on either upstream design or downstream processes. In the present study, we first expressed recombinant adalimumab through combination of the vector design and production process optimization in CHO cells. Bicistronic vector, monocistronic vector, and dual promoter vector were constructed, and the production process was optimized using low-temperature and fed-batch culture. The results showed that the dual promoter vector exhibited the highest yield under the transient and stable transfected cells among three different vector systems in CHO cells. In addition, low-temperature and fed-batch culture could further improve the yields of adalimumab. The purified antibody displayed tumor necrosis factor-α (TNF-α) binding activity. In conclusion, combination of expression vector design and production process optimization can achieve higher expression of recombinant mAbs in CHO cells. KEY POINTS: • The dual promoter vector is more effective for expressing recombinant antibodies. • The yields of antibodies are related to the LC chain expression level. • Low-temperature and feed addition can promote antibody production.
Collapse
Affiliation(s)
- Yongxiao Yang
- School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.,Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China
| | - Zhengmei Li
- School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.,Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China
| | - Qin Li
- Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China
| | - Kai Ma
- Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China
| | - Yan Lin
- Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China
| | - Huigen Feng
- School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
| | - Tianyun Wang
- Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang, 453003, Henan, China.
| |
Collapse
|
10
|
Schulze M, Kumar Y, Rattay M, Niemann J, Wijffels RH, Martens D. Transcriptomic analysis reveals mode of action of butyric acid supplementation in an intensified CHO cell fed‐batch process. Biotechnol Bioeng 2022; 119:2359-2373. [PMID: 35641884 PMCID: PMC9545226 DOI: 10.1002/bit.28150] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 05/17/2022] [Accepted: 05/28/2022] [Indexed: 11/10/2022]
Abstract
Process intensification is increasingly used in the mammalian biomanufacturing industry. The key driver of this trend is the need for more efficient and flexible production strategies to cope with the increased demand for biotherapeutics predicted in the next years. Therefore, such intensified production strategies should be designed, established, and characterized. We established a CHO cell process consisting of an intensified fed‐batch (iFB), which is inoculated by an N‐1 perfusion process that reaches high cell concentrations (100 × 106 c ml−1). We investigated the impact of butyric acid (BA) supplementation in this iFB process. Most prominently, higher cellular productivities of more than 33% were achieved, thus 3.5 g L−1 of immunoglobulin G (IgG) was produced in 6.5 days. Impacts on critical product quality attributes were small. To understand the biological mechanisms of BA in the iFB process, we performed a detailed transcriptomic analysis. Affected gene sets reflected concurrent inhibition of cell proliferation and impact on histone modification. These translate into subsequently enhanced mechanisms of protein biosynthesis: enriched regulation of transcription, messenger RNA processing and transport, ribosomal translation, and cellular trafficking of IgG intermediates. Furthermore, we identified mutual tackling points for optimization by gene engineering. The presented strategy can contribute to meet future requirements in the continuously demanding field of biotherapeutics production.
Collapse
Affiliation(s)
- Markus Schulze
- Product Development Cell Culture Technologies, Sartorius Stedim Biotech GmbHAugust‐Spindler‐Str. 1137079GöttingenGermany
- Bioprocess EngineeringWageningen UniversityPO Box 166700 AAWageningenNetherlands
| | - Yadhu Kumar
- Eurofins Genomics Europe Sequencing GmbHJakob‐Stadler‐Platz 7D‐78467KonstanzGermany
| | - Merle Rattay
- Corporate Research Advanced Cell Biology, Sartorius Stedim Cellca GmbHMarie‐Goeppert‐Mayer‐Str. 989081Ulm
| | - Julia Niemann
- Corporate Research BioProcessing Upstream, Sartorius Stedim Biotech GmbHAugust‐Spindler‐Str. 1137079GöttingenGermany
| | - Rene H. Wijffels
- Bioprocess EngineeringWageningen UniversityPO Box 166700 AAWageningenNetherlands
- Biosciences and AquacultureNord UniversityN‐8049BodøNorway
| | - Dirk Martens
- Bioprocess EngineeringWageningen UniversityPO Box 166700 AAWageningenNetherlands
| |
Collapse
|